Bharat Biotech's oral cholera vax clears phase-3 trials: Study
Hyderabad: Bharat Biotech, which has established an excellent track record of innovation with more than 145 global patents, a wide product portfolio of more than 19 vaccines, 4 biotherapeutics, has made a significant announcement.
Its oral cholera vaccine (OCV) Hillchol has demonstrated against both Ogawa and Inaba serotypes, proving non-inferior in healthy Indian adults and children, supporting its potential as an effective OCV. The above study findings have been published in the ScienceDirect, Vaccine journal 126998 to assess a double-blind, randomized phase III clinical trial to evaluate safety, immunogenicity, non-inferiority & lot-to-lot consistency of single component oral cholera vaccine Hillchol® in comparison to a comparator vaccine in a diverse participant group of 1,800 individuals, from infants to adults, across 10 clinical sites in India.
The primary endpoint focused on the proportion of participants achieving >4-fold increase in vibriocidal antibody titres against Ogawa and Inaba serotypes 14 days after two doses. While secondary endpoints included Geometric Mean Titre (GMT) measurements and safety.
Key highlights from the findings are as follows: Robust Immunogenicity: Hillchol® demonstrated a greater than 4-fold rise in vibriocidal antibodies against both Ogawa (68.3%) and Inaba (69.5%) serotypes, proving non-inferiority to licensed vaccines; and, Strong Safety Profile: Adverse events were mild and comparable between the two vaccines. Broad Age Coverage: The vaccine was well-tolerated and immunogenic across all age groups—including infants (≥1 year), children, and adults.
'This publication reaffirms our commitment to advancing vaccines built on rigorous research, thorough clinical trials, and reliable clinical data. It highlights our continued commitment to providing affordable, effective, and accessible vaccines for the populations who need them the most,' said Dr Krishna Ella, Executive Chairman, Bharat Biotech.
Dr Ella added, 'Cholera is a vaccine-preventable disease that has faced a surge in outbreaks along with a huge shortage of vaccines. The new generation Oral Cholera Vaccine Hillchol®, featuring a simplified single stable O1 Hikojima strain, inducing robust antibodies against both Ogawa and Inaba serotypes, aims to enhance production efficiency and affordability, particularly in lower- and middle-income countries where waterborne diseases continue to pose serious health threats.'
As cholera continues to threaten communities lacking clean water and sanitation, Hillcholprovides a streamlined, scalable solution designed to support global health programmes and ensure equitable access to life-saving vaccines.Global demand for OCVs is close to 100 million doses a year, and given that only one manufacturer supplies them, there is a global shortage. Bharat Biotech's facilities in Hyderabad and Bhubaneswar have a capacity to produce up to 200 million doses of Hillchol.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
3 hours ago
- Time of India
Musi river water unfit for drinking except at Osman Sagar: Study
Hyderabad: A scientific study published in the June edition of the Cleaner Water journal by ScienceDirect has found that water from the Musi River is unfit for drinking at all locations except at its upstream source, Osman Sagar. Tired of too many ads? go ad free now The research, titled 'Spatial and Seasonal Assessment of Water Quality of Musi River, India,' was led by Ajmal Koya Pulikkal of the Department of Chemistry, National Institute of Technology Mizoram, and co-authored by Mohammad Zakwan from Maulana Azad National Urdu University, Hyderabad. Water samples were collected from four stations — Osman Sagar (upstream), Bapughat and Musarambagh (midstream), and Nagole (downstream) — during the pre-monsoon, monsoon, and post-monsoon seasons. The study analysed 27 water quality parameters using standard methods and indices such as the Weighted Arithmetic Water Quality Index (WAWQI), Nemerow's Pollution Index, and various irrigation indices. The WAWQI values across the sites showed a sharp deterioration in water quality downstream: 38 at Osman Sagar, 175 at Bapughat, 197 at Musarambagh, and 179 at Nagole. Only Osman Sagar met the Bureau of Indian Standards for potable water. The deterioration became significant at Bapughat, attributed to urban encroachments, waste dumping, and sewage discharge. The study noted a slight improvement in water quality at Nagole, likely due to the Amberpet sewage treatment plant near Musarambagh. Seasonal and irrigation assessment reflect pollution load Seasonal analysis revealed further insights. While water from Osman Sagar remained suitable for both drinking and irrigation in all seasons (S-1 category), the other stations fell into S-3 (unsuitable for irrigation) during the pre and post-monsoon periods, and into S-2 (moderately suitable) during the monsoon, due to dilution effects. Tired of too many ads? go ad free now Kelley's index also indicated that only Osman Sagar's water was suitable for irrigation throughout the year. The study flagged declining dissolved oxygen levels and rising biochemical oxygen demand downstream. Hydrochemical facies analysis (a method used to interpret the chemical composition of water) using Piper diagrams further revealed a shift in water composition from upstream to downstream. The authors call for urgent and consistent monitoring, improved wastewater treatment, effective stormwater management, and stronger environmental regulation to reverse the degradation.
Time of India
a day ago
- Time of India
Is your sunscreen really protecting you? A new report reveals alarming truths behind that SPF label
As temperatures rise and beaches fill, most of us reach for the familiar tube of sunscreen, trusting it to be our shield against the sun's wrath. But a startling new report suggests that this trust may be misplaced. According to the Environmental Working Group's (EWG) 2025 Annual Guide to Sunscreens , a staggering majority of products lining U.S. store shelves may not be offering the protection they promise. In fact, fewer than one in four of the 2,200 SPF products evaluated met the organization's criteria for safety and effectiveness. Misleading Labels and Murky Regulations The report casts a harsh light on sunscreen manufacturers and regulatory bodies alike, accusing them of misleading claims and failure to update decades-old standards. Since 1999, federal sunscreen regulations have remained largely unchanged, leaving consumers at the mercy of marketing jargon and obscure ingredient lists. 'Many sunscreens still fall short,' the EWG warns, 'by offering misleading claims about protection and using outdated formulas—some even containing ingredients with potential health concerns.' Among the biggest culprits? Aerosol sprays, which make up 26% of all SPF products in 2025. Although the FDA proposed safety testing for these in 2019 due to inhalation risks and patchy application, it has yet to finalize these rules. Between 2021 and 2023, multiple sunscreen sprays were recalled due to benzene contamination, a known carcinogen—yet the market remains flooded with these popular but problematic products. The Fragrance Trap Another eyebrow-raising concern: undisclosed 'fragrances.' The report reveals that 36% of sunscreen products containing unspecified fragrance ingredients actually hide a cocktail of allergens, hormone disruptors, and even carcinogens. A 2022 federal law mandated the FDA to outline clear guidelines on fragrance allergens by July 2024. But as of May 2025, no such guidelines have been proposed. EWG attributes the delay to regulatory staffing shortages under the Trump administration, further complicating consumer safety efforts. Until transparency improves, the organization urges consumers to seek fragrance-free sunscreens or those bearing the EWG Verified® mark, which signifies ingredient clarity and the absence of harmful additives. The Fall of Oxybenzone and Vitamin A Some silver linings have emerged. Once a common ingredient in non-mineral sunscreens, oxybenzone has seen a dramatic fall from 70% usage in 2016 to just 9% in 2025. The compound is flagged not only for disrupting hormones but also for damaging marine ecosystems—a serious double threat. Vitamin A (often listed as retinyl palmitate) is another ingredient on the decline, found in only 2% of sunscreens today, down from 41% in 2010. Despite its skin-nourishing reputation, Vitamin A can degrade in sunlight, potentially worsening skin damage rather than preventing it. iStock Experts now urge consumers to opt for fragrance-free, mineral-based options and reapply frequently for real protection. (Representational Image: iStock) The Safer Path to Sun Protection So, what should a sunscreen-savvy shopper do in this minefield of misleading products? The EWG guide doesn't just criticize—it also educates. The top advice includes not falling for high SPF labels, which often give a false sense of security. Products boasting SPF 50+ may only offer marginally better protection than SPF 30, while encouraging users to stay in the sun longer than is safe. The guide recommends lotion or stick sunscreens over sprays, choosing mineral-based formulas with ingredients like zinc oxide, and using physical barriers like hats, sunglasses, and long-sleeved clothing. And perhaps most importantly: reapply often, especially after swimming or sweating. Sun safety is about more than what's in the bottle. With skin cancer rates rising, knowing what goes on your skin—and into your body—has never been more crucial. This summer, before you bask in the glow of sunshine, take a closer look at what you're trusting to guard your skin. The truth behind your SPF might not be as radiant as you think.
Time of India
4 days ago
- Time of India
Vizag's King George Hospital among 10 centres in country to participate in oral cholera vaccine trials
Visakhapatnam: King George Hospital in Visakhapatnam is one of 10 centres in the country that participated in phase III trials of oral cholera vaccine Hillchol, developed by Bharat Biotech. Tired of too many ads? go ad free now Of the 1,800 enrolled participants across these 10 sites, 1,794 completed the clinical study, which assessed the safety, immunogenicity, and non-inferiority of Hillchol in comparison to a comparator vaccine in this diverse participant group. Post-vaccination, the percentage of participants in the Hillchol group who exhibited a four-fold increase in anti-Vibrio cholerae antibody titres was 68.25% for Ogawa and 69.52% for Inaba. For the uninformed, among the various serotypes of the Vibrio cholerae O1 biotype, Ogawa and Inaba are primarily associated with cholera outbreaks, as they exhibit distinct antigenic variations in their lipopolysaccharide structure. Cholera is an acute diarrhoeal infection caused by ingesting food or water contaminated with Vibrio cholerae bacteria. Approximately, V. cholerae affects 1.3 to 4.0 million people per year, causing between 21,000 and 1.43 lakh deaths worldwide, predominantly in developing nations across Africa, Asia, and the Americas. Children under five years of age account for about half of all cases and deaths, although individuals of all ages are susceptible. The World Health Organisation (WHO) recently reported that the dynamics of cholera outbreaks are becoming increasingly complex, with a rise in the number of cases since 2021, highlighting the escalating challenge of controlling V. cholerae infections and transmission. The global demand for OCVs is close to 100 million doses per year. Tired of too many ads? go ad free now Yet, given that only a single manufacturer supplies them, a global shortage persists. According to Bharat Biotech, its facilities in Hyderabad and Bhubaneswar have the capacity to produce up to 200 million doses of Hillchol. The new-generation OCV, featuring a simplified single stable O1 Hikojima strain, aims to enhance production efficiency and affordability. It induces robust antibodies against both Ogawa and Inaba serotypes, improving accessibility, particularly in lower- and middle-income countries where waterborne diseases continue to pose serious health threats. A total of 1,800 participants were screened based on health status across the 10 trial sites to ensure a diverse demographic analysis. Participants with a history of cholera vaccination or infection, hypersensitivity to past vaccinations, immune disorders, significant acute symptoms, or recent treatment for diarrhoea were excluded. All trial sites were tertiary care centres, including KGH Visakhapatnam, located in urban areas. Participants were enrolled after obtaining informed consent. The other centres were located in states such as Maharashtra, Telangana, Uttar Pradesh, Goa, and Bihar. The trial achieved a completion rate of 99% (1,782 participants), with a discontinuation rate of 1% attributed to various reasons. No serious adverse events were reported, with the majority of adverse events being mild. According to the researchers, this highlights the safety of the vaccine as a viable OCV option and the reliability of its manufacturing processes. Its scalability and logistical benefits also highlight its potential to mitigate the OCV shortage. The study findings have been published in Vaccine, a journal from ScienceDirect.
